The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan.
 
Vijaya G Tirunagaru
Employment - Rain Therapeutics
Stock and Other Ownership Interests - Rain Therapeutics
Patents, Royalties, Other Intellectual Property - Rain Therapeutics
Travel, Accommodations, Expenses - Rain Therapeutics
 
Feng Xu
Employment - Rain Therapeutics
Stock and Other Ownership Interests - Rain Therapeutics
 
Trista Hinz
Research Funding - Rain Therapeutics
 
Lynn Heasley
Research Funding - Rain Therapeutics
 
Richard Bryce
Employment - Puma Biotechnology; Rain Therapeutics
Leadership - Puma Biotechnology; Rain Therapeutics
Stock and Other Ownership Interests - Puma Biotechnology; Rain Therapeutics
Travel, Accommodations, Expenses - Puma Biotechnology; Rain Therapeutics
 
Avanish Vellanki
Employment - Rain Therapeutics
Leadership - Rain Therapeutics
Stock and Other Ownership Interests - Rain Therapeutics
Patents, Royalties, Other Intellectual Property - Rain Therapeutics
 
Nora Ku
Employment - Rain Therapeutics
Stock and Other Ownership Interests - Rain Therapeutics
 
Robert Charles Doebele
Employment - Rain Therapeutics
Leadership - Rain Therapeutics
Stock and Other Ownership Interests - Rain Therapeutics
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; GreenPeptide; Guardant Health; Rain Therapeutics; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Licensing fees for patent from Rain Therapeutics; Licensing fees from Takeda for Biologic Materials; Licensing fees from ThermoFisher for Biologic Materials